Your browser doesn't support javascript.
loading
Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis.
Naumann, Nicole; Lübke, Johannes; Baumann, Sofie; Schwaab, Juliana; Hoffmann, Oliver; Kreil, Sebastian; Dangelo, Vito; Reiter, Lukas; Bugert, Peter; Kristensen, Thomas; Sotlar, Karl; Haselmann, Verena; Schneider, Sven; Metzgeroth, Georgia; Weiss, Christel; Popp, Henning D; Fabarius, Alice; Hofmann, Wolf-Karsten; Cross, Nicholas C P; Reiter, Andreas; Jawhar, Mohamad.
Afiliação
  • Naumann N; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Lübke J; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Baumann S; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Schwaab J; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Hoffmann O; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Kreil S; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Dangelo V; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Reiter L; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Bugert P; Institute of Transfusion Medicine and Immunology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Kristensen T; Mastocytosis Center, Odense University Hospital, 5000 Odense, Denmark.
  • Sotlar K; Department of Pathology, Odense University Hospital, 5000 Odense, Denmark.
  • Haselmann V; University Hospital Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
  • Schneider S; Institute for Clinical Chemistry, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Metzgeroth G; Institute for Clinical Chemistry, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Weiss C; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Popp HD; Department of Medical Statistics and Biomathematics, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Fabarius A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Hofmann WK; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Cross NCP; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, 68167 Mannheim, Germany.
  • Reiter A; School of Medicine, University of Southampton, Southampton SO17 1BJ, UK.
  • Jawhar M; Wessex Regional Genetics Laboratory, Salisbury SP2 8BJ, UK.
Int J Mol Sci ; 22(5)2021 Mar 04.
Article em En | MEDLINE | ID: mdl-33806359
ABSTRACT
In systemic mastocytosis (SM), qualitative and serial quantitative assessment of the KIT D816V mutation is of diagnostic and prognostic relevance. We investigated peripheral blood and bone marrow samples of 161 patients (indolent SM (ISM), n = 40; advanced SM, AdvSM, n = 121) at referral and during follow-up for the KIT D816V variant allele frequency (VAF) at the DNA-level and the KIT D816V expressed allele burden (EAB) at the RNA-level. A round robin test with four participating laboratories revealed an excellent correlation (r > 0.99, R2 > 0.98) between three different DNA-assays. VAF and EAB strongly correlated in ISM (r = 0.91, coefficient of determination, R2 = 0.84) but only to a lesser extent in AdvSM (r = 0.71; R2 = 0.5). However, as compared to an EAB/VAF ratio ≤2 (cohort A, 77/121 patients, 64%) receiver operating characteristic (ROC) analysis identified an EAB/VAF ratio of >2 (cohort B, 44/121 patients, 36%) as predictive for an advanced phenotype and a significantly inferior median survival (3.3 vs. 11.7 years; p = 0.005). In terms of overall survival, Cox-regression analysis was only significant for the EAB/VAF ratio >2 (p = 0.006) but not for VAF or EAB individually. This study demonstrates for the first time that the transcriptional activity of KIT D816V may play an important role in the pathophysiology of SM.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas c-kit / Mastocitose Sistêmica / Mutação Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas c-kit / Mastocitose Sistêmica / Mutação Tipo de estudo: Prognostic_studies / Qualitative_research Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2021 Tipo de documento: Article